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Abstract: The study’s objective was to assess the expressions of Fas and FasL proteins in gastric cancer in corre-
lation with chosen clinicohistological parameters. Fas and FasL expression was analyzed in 68 patients with
gastric cancer, using the immunohistochemical method. The expression of Fas was found to be lower in gastric
cancer cells than in healthy mucosa, both in the lining epithelium and in glandular tubes (28% vs. 48% and 44%;
p < 0.001). The expression of FasL was also markedly lower in cancer cells than in glandular tubes, yet higher
than in the lining epithelium (51% vs. 73% and 14%; p < 0.01). Positive expressions of FasL and Fas were lower
in less advanced gastric cancer cells (T1, T2), than in more advanced tumors (T3, T4), but only in the case of
FasL was this difference statistically significant (p < 0.05). Our findings seem to confirm the theory of the impact
of apoptotic disorders at the level of Fas receptor and FasL protein in the process of gastric cancer formation
and growth, which is manifested in the varied expressions of these proteins in gastric cancer and in the normal
lining and glandular epithelium of the stomach. However, the lack of significant differences in the expressions of
Fas and FasL in correlation to other clinicohistological parameters indicates the existence of mechanisms that
have a greater impact on the process of differentiation of gastric cancers. This in our opinion eliminates these
proteins as prognostic factors. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 1, pp. 142–147)
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Introduction
Tumor grade at the time of diagnosis and histological
type are key factors in the treatment of patients with
gastric cancer, affecting their survival after surgery.
Little is known of the factors that could determine the
respective histological type or those that affect tumor
growth rate or formation of distant metastases. These
issues are closely connected to the abnormal proces-
ses of gastric mucosal cell proliferation and disturbanc-
es in apoptosis, which is a natural defense mechanism.
A number of apoptosis-inducing factors have been
known so far. Two main apoptotic pathways have been
distinguished: external (membranous), due to mem-
brane Fas receptor stimulation; and internal (mito-
chondrial), largely dependent on the Bcl-2 family of
proteins. The ultimate effect is cell death as the re-
sult of enzyme activation.
The activation of TNF family membrane recep-
tors, including Fas (Apo-1, CD95), occurs after bin-
ding to a receptor-specific ligand molecule, the Fas-
ligand protein (FasL). Cytotoxic T lymphocytes that
have a FasL molecule on their surface act through
the Fas-FasL interaction. Following identification of
cells that are to be eliminated (e.g. neoplastic or in-
fected with viruses) T cells bind to their membrane
Fas receptor and trigger cell destruction. The Fas re-
ceptor has in its structure the so-called ‘death domain’
(DD) at the cytoplasmic side. Fas-ligand binding to
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the receptor causes activation of its death domain that
binds to FADD (Fas-associated death domain) — the
protein mediating caspase activation. The Fas —
FADD complex via its domain — DED (the death
effector domain) — activates precaspase 8 (the so-
called ‘FLICE’ protein (FADD-like interleukin 1 beta
converting enzyme). Caspase 8 (FLICE) through
caspase 10 activates the apoptotic effector protein,
caspase 3. There is another apoptotic model invol-
ving membrane receptors, through secondary intra-
cellular transmitters engaged in apoptosis, with cera-
mide as the final product (originates from sphyngo-
myelin under the effect of sphyngomyelinase). Its acti-
vation depends on the stimulation of membrane
receptors for TNF and Fas/APO-1, which results in the
production of death protein — FADD/Mort 1 and RIP
(after Fas receptor activation). These proteins affect
sphyngomyelinase that affects sphyngomyelin, giving rise
to ceramide which leads to caspase activation [1–4].
Despite growing understanding of apoptosis, the
question remains unanswered: Which apoptotic path-
way (and to what degree) becomes disturbed during
neoplastic transformation?
The objective of the current study was to compare
the expressions of Fas, FasL proteins in gastric carci-
noma cells and healthy non-neoplastic gastric mucosa
(lining and glandular epithelium). The expressions of
Fas and FasL were analyzed in relation to tumor histo-
logical type, histological malignancy grade (feature G),
degree of advancement (pT), location in the stomach
and the presence of Helicobacter pylori infection in the
stomach. The lifespan of patients was also investiga-
ted in relation to whether Fas and FasL could possibly
be prognostic factors in gastric cancer patients.
Material and methods
Patients
The study involved 68 patients operated on in the II
Department of General and Gastroenterological Sur-
gery, Medical University of Bialystok, between 1999
and 2004. The study group included 21 women and
47 men aged 31–79 years. The study was conducted
on the archive material consisting of paraffin cubes
with embedded tissues of gastric cancer. Healthy gas-
tric mucosa was obtained from the fragment of the
stomach excised during surgery, and this served as
the control group.
Immunohistochemistry
The expressions of Fas and FasL were determined
using the immunohistochemical method, in neoplas-
tic and healthy tissues (glandular and lining epitheli-
um). Formalin-fixed and paraffin-embedded tissue
specimens were cut on a microtome into 5 µm thick
sections. The sections were deparaffinized in xylenes
and hydrated in alcohols of decreasing concentrations.
In the case of Fas antibody, antigens became exposed
through citrate buffer heating (pH = 6.0) for 15 min-
utes. Following rinsing in PBS buffer (pH = 7.4), the
sections were incubated with primary antibodies: Fas
(mouse monoclonal antibody, Sc-8009, Santa Cruz
Biotechnology) and FasL (goat polyclonal antibody,
Sc-834-G, Santa Cruz Biotechnology). After perfor-
ming the reaction in LSAB technique (LSAB +Sys-
tem HRP, Dako, Poland) the antigen-antibody com-
plex was visualized using chromogen DAB (S3000,
Dako, Poland).
The expressions of Fas and FasL were semi-quan-
titatively assessed in the neoplastic cells. The expres-
sion was considered positive when found in more than
20% of neoplastic cells, and negative when observed
in fewer than 20% of these cells.
Helicobacter pylori
Giemsa’s method was used in order to confirm the
presence of the bacteria Helicobacter pylori.
Statistical analysis
The results underwent statistical analysis using the
Pearson’s c2 test. Distant survivals were assessed us-
ing the Kaplan–Meier curve, whereas Gehan–Wilcox-
on test was applied to compare the survivals. The dif-
ferences found were considered statistically signifi-
cant at p < 0.05, with greater differences at p < 0.01
and p < 0.001. Pairs of missing values were removed.
Results
The expression of Fas was found to be significantly
lower in gastric cancer cells than in healthy mucosa,
both in the lining epithelium and glandular tubes
(28% vs. 48% and 44%; p < 0.001). Similarly, the
expression of FasL was markedly lower in cancer cells
than in glandular tube cells, but higher than in the
lining epithelium (51% vs. 73% and 14%, p < 0.01)
(Table 1, Figure 1).
Positive expressions of FasL and Fas were lower in
the cells of less advanced gastric cancer (T1 and T2),
compared to the more advanced ones (T3 and T4),
although only in FasL was the difference statistically
significant (33% vs. 63%; p < 0.05). Protein expres-
sions were compared in relation to tumor location in
the stomach, feature G, Lauren’s and Bormann’s clas-
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sifications, patients’ age and gender and Helicobacter
pylori infection. No significant differences were found
between the respective groups of patients (Table 2).
The average distant survivals were assessed after
surgery, using the Kaplan–Meier curve, in Fas- and
FasL-positive patients and in those lacking Fas and
FasL expressions, and then compared using the Ge-
han–Wilcoxon test. Positive protein expression had
no effect on the survival time of the patients (Figu-
res 2, 3).
Correlations were compared between patients with
positive and negative expressions of Fas and FasL. No
Table 1. Comparison of Fas and FasL expressions in gastric cancer cells and in healthy gastric mucosa (lining and glandu-
lar epithelium, control group)
Variables Fas p Fas L p
+ – + –
Study group
      Gastric cancer 21 (28%) 55 (72%) 36 (51%) 35 (49%)
Control group
     Lining epithelium 13 (48%) 14 (52%) p < 0.001* 3 (14%) 19 (86%) p < 0.01*
    Glandular tubes 12 (44%) 15 (56%) p < 0.001* 16 (73%) 6 (27%) p < 0.01*
*Comparison with study group (gastric cancer)
A B
C D
Figure 1. Immunohistochemical staining. A. Fas expression in normal mucosa. B. Lower cytoplasmic Fas reaction in
gastric cancer cells. C. High FasL expression in main glandular tube cells. D. Weak FasL expression in gastric cancer cells.
Original magnification × 400
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statistically significant correlations were noted be-
tween the two proteins examined (p > 0.05).
Discussion
We presented the expressions of Fas and FasL pro-
teins — mediators of the receptor pathway of apop-
tosis in gastric cancer cells in correlation with chosen
morphological parameters and Helicobacter pylori in-
fection. Our own findings confirm the occurrence of
disorders in the membrane apoptotic pathway in gas-
tric cancer cells. The expressions of Fas and FasL in
cancer cells differed significantly from those noted in
healthy gastric mucosa. In the case of Fas, the expres-
sion was lower in cancer cells than in normal mucosa,
both in the lining and glandular epithelium (28% vs.
48% and 44%; p < 0.001).
On the other hand, the expression of FasL in can-
cer cells was markedly higher than in the lining epi-
thelial cells (51% vs. 14%; p < 0.01), and lower than
in the glandular epithelial cells (51% vs. 73%). A simi-
lar correlation concerning differences in the expres-
sion of Fas ligand in the stomach wall was observed
by Ishihara et al. [5] As shown by their findings, posi-
tive FasL expression in the gastric mucosa associated
with the presence of Helicobacter pylori infection oc-
curs only in glandular epithelial cells, not in the li-
ning epithelium.
Such results would be in agreement with the the-
ory of disturbances in the membrane apoptotic
pathway in cancer cells as the cause of neoplastic
transformation and would also confirm the cancer
immune escape. According to this theory, a reduc-
tion in the Fas receptor expression causes disor-
Table 2. Expressions of Fas and FasL in gastric cancer cells in correlation with clinicopathomorphological factors and
Helicobacter pylori infection
Variables Fas p FasL p
+ – + –
Age
        < 60 5 (24%) 16 (76%)
SN
12 (46%) 14 (54%)
SN
        ≥ 60 16 (34%)  31 (66%) 23 (55%) 19 (45%)
Gender
        Female 5 (24%) 16 (76%)
SN
10 (48%) 11 (52%)
SN
        Male 16 (34%) 31 (66%) 25 (53%) 22 (47%)
Infiltration depth (pT):
        pT1,2 4 (15%) 23 (85%)
SN
9 (33%) 18 (67%)
p < 0.05
        pT3,4 13 (32%) 28 (68%) 26 (63%) 15 (37%)
Lauren’s feature
        Intestinal type 8 (19%) 34 (81%)
SN
22 (52%) 20 (48%)
SN
        Diffuse type 9 (33%) 18 (67%) 13 (52%) 14 (48%)
G feature
        G1, G2 4 (16%) 21 (84%)
SN
14 (56%) 11 (44%)
SN
        G3 17 (33%) 34 (67%) 22 (43%) 29 (57%)
Tumor location in the stomach
        Upper 2/3 6 (19%) 26 (81%)
SN
16 (50%) 16 (50%)
SN
        Lower 1/3 11 (31%) 24 (69%) 19 (54%) 16 (46%)
Bormann’s classification
        0, 1, 2 12 (29%) 30 (71%)
SN
23 (51%) 19 (49%)
SN
        3, 4 4 (21%) 15 (79%) 11 (52%) 8 (48%)
Helicobacter pylori infection
        Present 9 (22%) 32 (78%)
SN
18 (51%) 17 (48%)
SN
        Absent 12 (34%) 23 (66%) 18 (56%) 23 (44%)
SN — statistically nonsignificant
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ders in the apoptotic pathway in cancer cells which
become resistant to stimulation by FasL. At the
same time, high expression of FasL on the surface
of the neoplastic cells results, through Fas recep-
tor binding, in apoptosis in T lymphocytes, which
decreases the immune response of the patient [1–3,
6–10]
We found a slightly higher expression of Fas pro-
tein in more advanced cancers (T3 and T4) than in
the less advanced ones (T1, T2) (32% vs. 15%). This
difference, however, was not statistically significant.
Also, Osaki et al. [11] did not observe any signifi-
cant differences in Fas expression between adenomas
and early and advanced forms of cancer (38% vs.
43% vs. 37%). Similarly, Liu et al. [7] found no dif-
ferences in the expressions of Fas and FasL in rela-
tion to cancer advancement. On the contrary, Ohno
et al. [8] showed higher expression of Fas protein in
early forms of cancer compared to advanced ones
(70% vs. 64%), explaining this as a possible protec-
tive effect of this protein inhibiting tumor growth
through apoptosis induction.
We found a significantly higher expression of FasL
in more advanced tumors (T3 and T4) than in the
less advanced lesions (T1 and T2) (63% vs. 33%; p <
< 0.05), which would be consistent with the theory of
the ‘immune escape’ that accelerates tumor growth.
A similar correlation has been reported by other au-
thors [11, 12].
Zheng et al. [10] found significantly higher FasL
expression in gastric cancer cells than in normal mu-
cosa (53% vs. 34%; p < 0.001) and its lower expres-
sion in metastatic tumors than in primary lesions (51%
vs. 81%; p < 0.05).
Similarly to our findings, most authors showed no
significant correlations between FasL expression and
depth of gastric wall infiltration [7, 8, 11, 13].
Our own findings, as well as the reports of some au-
thors showing varying expressions of apoptosis-associa-
ted proteins in gastric cancer cells depending on tumor
grade, could indicate that the factors affecting tumor
growth or metastasizing may result from various apop-
totic disorders. This, however, requires further study.
Like most authors, we found no significant correla-
tion between protein expressions and patients’ age or
gender [7], although higher Fas and FasL expressions were
noted in patients over 60 years of age (Fas: 19% vs. 38%;
FasL: 46% vs. 55%). This difference, however, was not
statistically significant (p > 0.05). Ohno et al. [8] noted
a higher expression of FasL in patients over 60.
In our study, Fas expression according to Lau-
ren’s classification was observed in 33% of diffuse
cancers, compared to 19% of intestinal-type tumors.
Ohno et al. [8] showed higher Fas expression in in-
testinal cancer cells than in the diffuse type, explai-
ning this as more substantial disorders in the mem-
brane apoptotic pathway in the case of more malig-
nant cancers. We found no difference was in the ex-
pression of FasL in various histopathological forms
of cancer (52% vs. 52%). These results are consis-
tent with literature data [7, 9]. On the other hand,
other authors have demonstrated higher FasL ex-
pression in intestinal-type cancer cells as compared
to the diffuse type [1, 10, 14].
The assessment of the protein expression depending
on the feature G, tumor location in the stomach and
Bormann’s classification did not show any significant
differences between the respective groups of patients.
Figure 2. Comparison of survival rates in patients with
positive Fas expression and its lack
Figure 3. Comparison of survival rates in patients with
positive FasL expression and its lack
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Similar results were obtained by Ohno et al. [8]
and Benett et al. [13] who revealed, like Zheng [10],
higher FasL expression in larger tumors.
The results could suggest that the type of apop-
totic disorders is to a lesser degree dependent on tu-
mor location in the stomach and that the macroscop-
ic form of cancer (Bormann) depends on other fac-
tors than the disturbed membrane pathway.
The effect of Helicobacter pylori infection, one of
the commonest carcinogenic factors, on Fas and FasL
expressions was also assessed. No significant differe-
nce was noted in the expressions of proteins exam-
ined depending on the presence of the infection, al-
though the expressions of both proteins were slightly
lower in the infected patients. These results prove
a slight effect of Helicobacter pylori infection on the
disturbances of this apoptotic pathway and are con-
sistent with literature data [15, 16].
We found no significant differences in the surviv-
al rate of patients depending on the protein expres-
sion. Some authors have reported longer survival in
Fas-positive patients suggesting that high expression
of this protein may have an inhibitory effect on tu-
mor growth, associating the degree of Fas-dependent
apoptotic pathway disorders with the occurrence of
more aggressive forms of tumor and shorter survival
of patients [9].
Our own results, presented here, confirm the
theory of the effect of apoptotic disorders at the
level of the Fas receptor in the process of forma-
tion and progression of gastric cancer. However,
lack of significant differences in correlation with
tumor malignancy, differentiation, macroscopic
form, location in the stomach, or Helicobacter py-
lori infection seems to suggest the existence of
mechanisms that have a greater effect on gastric
cancer differentiation. Additionally, lack of signifi-
cant difference in distant five-year-survival depend-
ing on Fas and FasL expressions excludes these pro-
teins from being the prognostic factors some au-
thors have suggested them to be [8]. However, it
should be emphasized that our knowledge of the
impact of apoptotic disorders on tumor formation
and growth, or on the occurrence of distant me-
tastases, is still slender. The problem requires tho-
rough study in order to improve the future diagno-
sis and treatment of gastric cancer [3].
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